Vertex Pharmaceuticals Incorporated vs State Street Technology Select Sector SPDR ETF — how do they compare? Vertex Pharmaceuticals Incorporated trades at $481.47 (market cap $121.95B), while State Street Technology Select Sector SPDR ETF trades at $180.7. Which is the better fit depends on your goals.
| VRTX | XLK | |
|---|---|---|
Market Cap | $121.95B | — |
Sector | Health | Sector/Thematic |
52-Week High | $529.59 | $198.21 |
52-Week Low | $366.54 | $127.49 |
Enterprise Value | $116.69B | — |
Trailing returns across standard periods
Latest headlines on both assets
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →XLK tracks the Technology Select Sector Index, providing targeted exposure to the largest and most influential technology companies within the S&P 500. It is a highly concentrated, liquid vehicle focused on software, semiconductors, and hardware leaders, serving as the primary benchmark for U.S. large-cap technology performance.
Read more on XLK →